Burgundy Clinical Trial
Patients with Wet Macular Degeneration (open for recruitment)
This is a surgical device trial that is investigating the safety and effects of an investigational medication delivered continuously from the Port Delivery System. This study is for participants with Neovascular Age-Related Macular Degeneration.
Neovascular Age-Related Macular Degeneration is a disease of the eye that can affect the retina, and particularly the macula. This can affect detailed, central vision.
The Port Delivery system is FDA approved. This study is looking at the effects and safety of an investigational medication delivered via the Port Delivery System to potentially reduce the number of eye injections needed for nAMD.
Ascent Gene Therapy Clinical Trial
Patients with Wet Macular Degeneration (open for recruitment)
We are conducting a clinical trial to evaluate a gene therapy product called RGX-314 for patients with choroidal neovascularization (CNV), a form of wet age-related macular degeneration (AMD). CNV causes progressive damage to the macula, the central region of the retina (inside the eye), which is involved in the fine details associated with reading, driving, and recognizing faces. In the advanced stage of the disease, CNV results in severe central vision loss. This impairs performance of many activities of daily living.
Currently available anti-VEGF agents approved for the treatment of CNV may improve vision over time but these therapies must be re-administered often to prevent the disease from worsening. There is a significant need for a long-acting therapeutic in patients with nAMD to reduce injection burden. The purpose of this study is to evaluate the safety and efficacy of a single RGX-314 subretinal injection in participants with nAMD compared to repeated intravitreal (ITV) injections.
Portal Clinical Trial
Patients with Wet Macular Degeneration (closed for recruitment)
AMD is the leading cause of blindness in people over 50 years of age. It is caused by the breakdown of the central portion of the retina (the nerve layer part of your eye that works like the film in a camera to pick up the picture) called the macula. The macula is responsible for the fine central vision in the eye that is needed for driving a car, reading fine print, recognizing faces, etc.
There are two types of macular degeneration: dry (non-neovascular) and wet (neovascular). In the "wet" form of AMD, abnormal blood vessels grow in the back of the eye. Sometimes these vessels leak blood or fluid that causes blurred and distorted vision. This process is also known as choroidal neovascularization (CNV). For people affected by "wet" AMD, vision loss may be quick and severe. This study is for participants with "wet" AMD. The purpose of this study is to evaluate the effects of investigational drug in research participants with wet AMD, and how it is absorbed into the body, when administered in combination with other AMD drugs. An investigational drug is one which has not been approved by the U.S. Food and Drug Administration (FDA) but is available in research studies like this one.